Grupa Azoty and Orlen have agreed to continue to work on the terms of a potential transaction whereby Orlen – or another entity designated by Orlen – would acquire all or a portion of the shares currently held by Grupa Azoty in Grupa Azoty Polyolefins or otherwise execute the investment.
Barentz, a global specialty ingredients provider, recently announced the acquisition of NCD Ingredients, a specialty, personal, and home care ingredients distributor active in Germany, Austria, and Switzerland (DACH). The acquisition enhances Barentz’s presence in the DACH region, with a particular focus on Germany—the second-largest personal care market in EMEA.
IMCD, a global distribution and formulation partner of specialty chemicals and ingredients, has agreed to acquire the personal care and pharmaceutical business of YCAM, a distributor based in South Korea.
In a move to expand its oncology business, GSK is nearing a $1 billion deal to buy a US biotech developing a treatment for rare gastrointestinal tumors.
Ashland recently announced that it has signed a definitive agreement to sell its Avoca business to Mane. The transaction is expected to close in the calendar first quarter 2025, subject to the satisfaction of customary closing conditions.
As part of its long-term plans in the country, US drugmaker Merck & Co., operating as MSD outside of North America, has acquired WuXi Biologics’ site in Dundalk, Ireland, for about $500 million. The deal was announced through Ireland’s Foreign Direct Investment Agency (IDA) and MSD’s Ireland unit.
Stockholm, Sweden-headquartered global rare disease company Immedica Pharma has agreed to acquire Marinus Pharmaceuticals, a US commercial-stage pharmaceutical company developing therapies for seizure disorders, for enterprise value of approximately $151 million.
China’s Hutchmed has agreed to divest its 45% equity interest in Shanghai Hutchison Pharmaceuticals Ltd. (SHPL) for approximately $608 million (4,478 million renminbi) in cash, to China-based private equity firm GP Health Service Capital and Shanghai Pharmaceuticals.
US biopharma AbbVie has signed an agreement to acquire US biotechnology company Nimble Therapeutics, including its lead asset, an investigational oral peptide IL23R inhibitor in preclinical development for the treatment of psoriasis and a pipeline of other novel oral peptide candidates with potential across several autoimmune diseases.
In 2024, the chemical distribution industry is at a pivotal moment, navigating both challenges and new opportunities. As distributors grapple with a landscape shaped by shifting global trade routes, demand constraints, and digital disruption, their roles are evolving far beyond traditional bulk breaking.
H.B. Fuller Company, the largest pure-play adhesives company in the world, recently announced that it has signed agreements to acquire two leading medical adhesive technology companies, GEM S.r.l. and Medifill Ltd.
Arkema recently finalized the acquisition of Dow’s flexible packaging laminating adhesives business. This acquisition will significantly expand Arkema's portfolio of solutions for flexible packaging, positioning the company as a key player in this attractive market.
Roche has entered into a definitive merger agreement to acquire Poseida Therapeutics, a US clinical-stage biopharmaceutical company developing donor-derived CAR-T cell therapies, in a deal valued at approximately $1.5 billion.
Swiss pharmaceutical giant Novartis has acquired Kate Therapeutics for $1.1 billion. The San Diego, US-headquartered preclinical stage biotechnology company develops adeno-associated virus (AAV)-based gene therapies to treat inherited neuromuscular diseases.
International Chemical Investors Group (ICIG) has acquired the European Advanced Organics business from Valtris Specialty Chemicals. The transaction includes production plants in Tessenderlo, Belgium, and Maastricht, the Netherlands, as well as the benzyl chloride and derivatives portfolio manufactured at those sites.
US-headquartered Avid Bioservices, a biologics-oriented CDMO, will be acquired by funds managed by GHO Capital Partners and Ampersand Capital Partners in an all-cash transaction valued at approximately $1.1 billion. The three companies have signed a corresponding agreement.
US specialty chemicals company Solenis has acquired BASF’s flocculants business for mining applications. With this strategic acquisition, Solenis enhances its portfolio for mining and mineral processing customers. The transaction, for which financial details were not disclosed, was first announced in July.
US drugmaker AbbVie has signed an agreement to acquire biotechnology company Aliada Therapeutics, which develops therapies for central nervous system (CNS) diseases using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases.
LyondellBasell (LYB) has completed its acquisition of APK in Merseburg, Germany. The company will be fully integrated and continue as part of LYB. The deal was first announced in August of this year.
US paints and coatings group PPG has reached a definitive agreement to sell 100% of its architectural coatings business in the US and Canada to investor American Industrial Partners (AIP) for $550 million.
Sanofi has entered into talks with Clayton Dubilier & Rice (CD&R), a US-based investment company, about the potential sale of a 50% controlling stake in the French drugmaker‘s consumer healthcare business, Opella.
Danish drugmaker Lundbeck has announced to acquire US company Longboard Pharmaceuticals in a deal valued at approximately $2.6 billion. Longboard, headquartered in La Jolla, California, is a clinical-stage biopharmaceutical company focused on developing novel medicines for neurological diseases.
Sudarshan Chemical Industries Limited (SCIL) recently announced that it has entered into a definitive agreement with the Germany-based Heubach Group, on its acquisition in a combination of an asset and share deal. Sudarshan aims to expand its global presence and pigment portfolio across 19 sites to provide customers with a top-tier product range.
OneSource Specialty Pharma, a newly incorporated CDMO, formed from the merger of three CDMO businesses within the Strides Group. The company has a 30-year track record and specializes in biologics, drug-device combinations, and soft gelatin capsules.
Rio Tinto announced that it will acquire Arcadium Lithium in an all-cash transaction for $5.85 per share that values Arcadium’s at approximately $6.7 billion.
Lonza has completed its acquisition of the Genentech large-scale biologics manufacturing site in Vacaville, California, USA, from Roche for $1.2 billion. The deal was announced in March of this year.
Azelis has signed an agreement to acquire 100% of the shares of Hortimex, a specialty chemicals distributor active in the food ingredients and nutraceuticals segments serving the Polish market.
Keen Vision Acquisition Corp. (KVAC) and Medera, a clinical-stage biotechnology company, have entered into a merger agreement. Upon closing of the merger, which is expected to occur in the fourth quarter of 2024, the combined company will operate under the name Medera.
Belgium-headquartered biopharmaceutical company UCB is to sell its mature neurology and allergy business in China to Singapore-based asset management group CBC and investor Mubadala, based in Abu Dhabi, for $680 million.
US paints and coatingsmaker PPG has agreed to sell its silicas products business for abou $310 million to Warsaw, Poland-based Qemetica, a manufacturer of soda ash, silicates and other specialty chemicals. The transaction is expected to close in the fourth quarter of 2024, subject to customary closing conditions.
US industrial gases producer Air Products has agreed to acquire Saneg’s hydrogen production assets at the Fergana oil refinery in Uzbekistan for $140 million.
In a move to grow and upgrade its circular and low carbon solutions business, chemical producer LyondellBasell is to acquire full ownership of plastic recycler APK in Merseburg, Germany. Closing of the transaction is subject to customary closing conditions. Financial details of the deal have not been disclosed.
Bora Pharmaceuticals, a Taiwan-headquartered contract development and manufacturing organization (CDMO), has completed the acquisition of Emergent BioSolutions' sterile manufacturing facility in Baltimore-Camden, Maryland, USA. The facility adds drug product fill/finish to Bora’s extensive biologics drug substance capabilities.
Eli Lilly has completed its acquisition of Morphic, is a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases. The $3.2 billion deal was initially agreed upon by the companies in July 2024.
Manuchar, a global chemical distributor with headquarters in Antwerp, Belgium, has agreed to acquire a majority stake in Chilean company Proquiel Químicos.
